GLP-1 Agonist Drugs and Muscle Loss: What is the Cure? by Jerry Brainum 3/26

 

 

Until recently, glucagon-like peptide-1 (GLP-1) was an obscure gut hormone known mainly to physicians who treat diabetes. Like insulin, GLP-1 is released following a meal and plays a central role in regulating blood glucose levels. Yet its potential extends well beyond blood sugar control. GLP-1 slows gastric emptying, keeping food in the stomach longer and thereby promoting a sense of fullness that curbs the desire to eat — a mechanism now recognized as valuable in treating obesity. It also promotes diuresis, helping the body shed excess water. Beyond these metabolic effects, GLP-1 appears to benefit cardiovascular health and offers neuroprotective properties, including the preservation of cognitive function and the reduction of neuroinflammation, a key driver of many age-related conditions.

The idea that the intestine secretes a substance that aids insulin activity was first recognized in 1968. The newly discovered compound bore a structural resemblance to glucagon, a pancreatic hormone, but functionally it worked differently — rather than opposing insulin, it enhanced glucose uptake. Because it was a shorter chain of amino acids than a full protein, it was classified as a peptide, and given its structural similarity to glucagon, it was named glucagon-like peptide-1, or GLP-1. Research soon revealed a significant obstacle to its clinical use: GLP-1 was degraded by the body within roughly six minutes of being released, making it impractical as a drug in its natural form. Still, its ability to work alongside insulin to regulate blood glucose made it an attractive model for a new class of diabetes medications. Other drugs for type-2 diabetes already existed, but most — metformin being a notable exception — carried side effect profiles that made them unpopular with patients. Pharmaceutical companies, therefore, set out to develop synthetic compounds that mimicked GLP-1's action, known as GLP-1 agonists, and to bring them to market as diabetes treatments. Although these drugs also produced meaningful weight loss by reducing appetite and slowing gastric emptying, that effect was largely set aside; the initial commercial focus was squarely on blood sugar control.

The central challenge facing researchers was GLP-1's fleeting presence in the body. The culprit was a specific enzyme, DPP-4, which degrades GLP-1 within minutes of its release. The key to overcoming this obstacle came from an unexpected source: the Gila monster. Scientists had previously identified a compound in the lizard's saliva — exendin-4 — that mimics GLP-1 but resists DPP-4 breakdown, allowing it to remain active in the body far longer. This discovery provided the conceptual blueprint for engineering stable, long-acting GLP-1 agonists. Modern drugs in this class, such as semaglutide, sold under trade names including Ozempic and Wegovy, are fully synthetic compounds designed on that principle, offering activity lasting up to a week from a single subcutaneous injection. Because these drugs are peptides, oral ingestion would normally destroy them in the digestive tract — but . . .